Alpha-1 antitrypsin (AAT) deficiency is a common monogenic disorder in which there is a strong founder effect of a single missense mutation in SERPINA1, the gene encoding this major circulating serum anti-protease that is normally expressed primarily in hepatocytes. These features make AAT deficiency particularly attractive as a target for therapeutic gene editing using a wide variety of approaches.
Keywords: Alpha-1 antitrypsin; CRISPR–Cas9; Emphysema; Gene editing; Gene therapy; Liver; Lung; Vector.
© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.